<DOC>
	<DOCNO>NCT00028275</DOCNO>
	<brief_summary>This study test whether gamma interferon effective treating chronic hepatitis C infection-a long-lasting viral infection affect liver . One-third patient hepatitis C infection develop cirrhosis liver , lead liver failure liver cancer . The current treatment hepatitis C infection pegylated alpha interferon ( peginterferon ) plus ribavirin ; however , treatment successful half patient . Gamma interferon work similarly alpha interferon , different pathway , therefore might helpful patient respond alpha interferon . Patients 18 year age old chronic hepatitis C infection , genotype 1 , respond alpha interferon ribavirin therapy may eligible study . ( Genotype 1 strain hepatitis C virus lower treatment success rate . ) Potential participant admit NIH Clinical Center 2 3 day medical evaluation determine eligibility study , enrol , begin gamma interferon therapy . Screening include medical history physical examination , blood urine test , possibly chest X-ray , abdominal ultrasound , psychiatric evaluation . Participants receive injection gamma interferon skin 3 time week 4 week ( total 12 injection ) . They randomly assign receive either 100 200 microgram drug per injection . Blood drawn first injection 6 , 12 , 24 48 hour later monitor change level hepatitis C virus immune response treatment . The amount rapidity decrease virus compare occur alpha interferon treatment define relative effectiveness gamma interferon . ( Patients may leave hospital time first day , must return time final blood test . ) Patients see clinic week treatment report symptom drug side effect blood drawn routine test viral level . After 4-week treatment complete , patient return follow-up visit week 6 8 routine blood test .</brief_summary>
	<brief_title>Gamma Interferon Therapy Chronic Hepatitis C</brief_title>
	<detailed_description>We treat 20 patient chronic hepatitis C use gamma interferon 1b dos either 100 200 mcg thrice weekly four week monitor regular , timed interval hepatitis C virus ( HCV ) RNA level immunological response HCV antigen . Patients chronic hepatitis C eligible fail respond previous course alpha interferon ribavirin raise serum aminotransferase level , HCV genotype 1 HCV RNA serum level great 10,000 copies/ml . The 20 patient include 10 patient treat become HCV RNA negative therapy ( Group A : non-responders ) 10 treat become HCV RNA negative therapy relapse thereafter ( Group B : relapsers ) . After medical evaluation monitoring HCV RNA level , patient randomize receive either 100 200 mcg gamma interferon 1b ( provide InterMune Pharmaceuticals , Inc ) subcutaneously three time weekly 4 week . Patients blood test HCV RNA level 0 , 6 , 12 , 18 , 24 , 48 hour initial injection weekly treatment , follow 2 4 week thereafter . T cell response HCV antigen assess treatment , 4 week therapy 4 week thereafter . Patients also monitor side effect change routine liver test complete blood count . This pilot study small number patient aim assess whether gamma interferon antiviral immunological effect hepatitis C , whether effect appear dose relate , whether similar timing degree alpha interferon . Demonstration antiviral effect would lead extensive trial large number patient , treat long period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 18 year , male female . Serum alanine asparate aminotransferase activity upper limit normal ( ALT great 41 AST great 31 IU/L ) . Presence antiHCV serum . Presence HCV RNA genotype1 serum level 10,000 copies/ml . Previous adequate therapy alpha interferon ribavirin without sustained virological response . An adequate course therapy define least 24 week alpha interferon start dos 3 million unit thrice weekly ribavirin start dos least 1000 mg daily . Patients initiated therapy dos , require dose modification due side effect also eligible . Written informed consent . EXCLUSION CRITERIA : Decompensated liver disease , mark bilirubin great 4 mg % , albumin less 3.0 gm % , prothrombin time great 2 sec prolong , history bleed esophageal varix , ascites hepatic encephalopathy . Patients ALT level great 1000 U/L ( great 25 time ULN ) enrol may follow three determination level . Pregnancy , woman childbearing potential spouse woman , inability practice adequate contraception , define vasectomy men , tubal ligation woman , use condom spermacide , birth control pill , intrauterine device . Significant systemic major illness liver disease , include congestive heart failure , ischemic heart disease , angina pectoris , cerebrovascular disease , renal failure ( creatinine clearance le 50 ml/min ) , organ transplantation , serious psychiatric disease depression . Preexisting , severe bone marrow compromise ; anemia ( hematocrit le 34 % ) , neutropenia ( less 1000 polymorphonuclear cells/mm ( 3 ) ) thrombocytopenia ( le 70,000 cells/mm ( 3 ) ) . Evidence another form liver disease addition viral hepatitis ( example autoimmune liver disease , Wilson 's disease , alcoholic liver disease , hemochromatosis , alpha1antitrypsin deficiency ) . Active substance abuse , alcohol , inhale injection drug within previous six month . Serious autoimmune disease , opinion investigator , might worsen interferon therapy , lupus erythematous , rheumatoid arthritis Crohn 's disease . Evidence hepatocellular carcinoma ; either alphafetoprotein ( AFP ) level great 50 ng/ml ( normal less 9 ng/ml ) and/or ultrasound ( image study ) demonstrate mass suggestive liver cancer . Human immunodeficiency virus infection , show presence antiHIV .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Viral Resistance</keyword>
	<keyword>Alpha Interferon</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis</keyword>
</DOC>